Merck Seals $11.3B Bio-Techne Deal; Lilly Expands Sleep Portfolio

Merck & Co. ($MRK) completed an $11.3 billion merger with Bio-Techne ($TECH), sending Bio-Techne shares surging 20% to close at $70.70. The acquisition expands Merck's position in life sciences tools and research reagents, adding Bio-Techne's portfolio of analytical instruments and bioprocessing solutions to its existing capabilities. Bio-Techne rallied for a third consecutive session as investors responded to the strategic value of the combination. The deal represents one of the largest life sciences M&A transactions of 2026 and underscores pharmaceutical companies' interest in vertically integrating research and development infrastructure.

Eli Lilly and Company ($LLY) completed its acquisition of Centessa Pharmaceuticals on June 24, advancing development of orexin receptor 2 agonists designed to treat narcolepsy and other sleep-wake disorders. The transaction adds a novel mechanism of action to Lilly's neuroscience portfolio by targeting the brain's sleep-wake regulatory pathways. Separately, $LLY participated in a $100.00 million follow-on equity offering for Absci Corporation alongside other institutional investors, backing the biotech's ABS-201 program after encouraging interim Phase 1 data from the HEADLINE trial in androgenetic alopecia. The trial demonstrated favorable safety and an estimated half-life of at least 65 days, with the program advancing to a multiple ascending dose stage. President Trump praised Lilly's U.S. investment plans during a Pennsylvania rally, according to reports tracked by political stock-monitoring accounts.

AbbVie Inc. ($ABBV) received European Commission approvals extending Skyrizi to children with moderate to severe plaque psoriasis and making Maviret the only therapy cleared in the EU for both acute and chronic hepatitis C infection from age three. The label expansions open earlier treatment windows and add pediatric populations in immunology and virology, broadening AbbVie's addressable patient base. Skyrizi's new pediatric indication strengthens its positioning in the dermatology market, while Maviret's expanded approval consolidates its leadership in hepatitis C across age groups. The pediatric expansions represent a strategic effort to establish therapeutic relationships earlier in disease progression and extend product lifecycles ahead of future patent expirations.

Thermo Fisher Scientific Inc. ($TMO) showcased new Orbitrap mass spectrometry upgrades, AI-powered software, and integrated laboratory solutions at the BIO International Convention 2026 in San Diego. The company highlighted end-to-end, AI-enabled capabilities across pharma services and bioproduction, positioning itself as a single integrated partner for drug development from discovery through manufacturing. $TMO shares traded at $505 amid mixed recent performance, with a 7-day return of 8.9% and a 30-day return of 12.8%, set against a year-to-date decline of 14.6% but a one-year gain of 23.2%. The product announcements underscore Thermo Fisher's ambition to integrate artificial intelligence and automation into core analytical workflows for biopharma clients.

Bristol-Myers Squibb Company ($BMY) offers a 4.7% dividend yield with strong profitability and value scores, according to ChartMill analysis, though high payout ratio concerns persist. Analysts cited Pfizer Inc. ($PFE) as a high-yield defensive stock pick for broad market bearishness, with investors rotating into oversold defense-oriented names and building cash reserves. Abbott Laboratories ($ABT) traded at $90.53 after tech-sector compression dragged the stock below $91, despite double-digit growth in its medical devices unit and a compounding diabetes franchise led by FreeStyle Libre. The defensive rotation reflects investor caution amid mid-year market volatility and concerns about AI and memory sector valuations.

UnitedHealth Group Incorporated ($UNH) closed at $415.53, gaining 2.4% as the managed care giant outperformed the broader market. Johnson & Johnson ($JNJ) rose 1.61% to $244.88, while Gilead Sciences, Inc. ($GILD) declined 1.05% to $123.84. Defensive healthcare names showed relative strength amid broader market volatility, with investors favoring established pharmaceutical and managed care companies over higher-risk biotechnology equities. Regeneron Pharmaceuticals, Inc. ($REGN) announced it will report second quarter 2026 financial and operating results on Thursday, July 30, 2026, before U.S. financial markets open, with a conference call scheduled for 8:30 AM Eastern Time.

Candel Therapeutics, Inc. appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head. Sims will lead commercial strategy for the oncology-focused biotech, bringing experience directing commercial operations for one of AstraZeneca's largest business franchises. Moderna, Inc. ($MRNA) published a slide deck on advancements in mRNA technology, clinical modalities, and future horizons in science. The company's shares have doubled year-to-date as investors anticipate upcoming catalysts beyond its pandemic-era vaccine portfolio.